Intravitreal Implants
·
Dexamethasone intravitreal implant (DEX implant; Ozurdex,
Allergan, Irvine, CA)
o
delivers the steroid intravitreally for 6 months
o
consists of poly (lactic-co-glycolic acid), a DEgradable
polyester and dexamethasone
o
single-use applicator through a 22-gauge
o
uveitis and macular edema caused by retinal vein occlusion
o
350 µg and 700 µg version
o
Uses NOVADUR Delivery
system
o
GENEVA
(dexamethasone implant) study: Global Evaluation of implantable dexamethasone
in retinal Vein occlusion with macular edema (GENEVA) study
·
Vitrasert ganciclovir implant
o
poly(vinyl alcohol) and poly(ethylene vinyl
acetate)
o
delivers the medication for approximately 32 weeks (8 months) and has been shown
to halt the progression of CMV
o
nondegradable
o
5/4.5 mg
implant
o
Releases
1 mcg/ hour
o
Approaches concentration of 4 ug/ml intravitreal
·
Retisert fluocinolone implant
o
blend of the drug with poly(vinyl alcohol) and
methylcellulose
o
0.59 mg
pellet embedded in a nonbiodegradable scaffold designed to be implanted
in the vitreous cavity via a sclerotomy and anchored by a suture to the eye
wall
o
releases drug at steady state between 0.3 and 0.4µg/day for approximately 30 months
o
used most commonly for treatment of chronic non-infectious posterior uveitis.
o
Studied for DME
also
·
Iluvien fluocinolone implant
o
narrow cylinder 3.5 × 0.37 mm
o
25-gauge
o
lowest dose format (0.2 µg/day)
o
higher-dose (0.5 µg/day) system
o
FAVOR
(iluvien) study
·
I-vation triamcinolone implant
o
helical
screw coated with triamcinolone acetonide that delivers the drug
intravitreally for 36 months
o
25-gauge
o
drug is entirely within the coating on the helical structure
and not within the bulk of the device
·
ECT CNTF Implant
o
which allows the intravitreal implantation of a
chamber containing live cells programmed to release CNTF
o
1.5 ng/day
o
possible efficacy for age-related macular degeneration
(AMD) involving geographic atrophy and for RP
o
2 years or more
·
ECT technology anti-VEGF implant
o
NT-503
o
For ARMD
·
Brimonidine Intravitreal Implant
o
Patients With Geographic Atrophy Due to
Age-related Macular Degeneration (AMD)
o
This is a randomized, double-masked,
dose-response, sham-controlled evaluation of the safety and efficacy of
brimonidine tartarate intravitreal implant in patients with geographic
atrophy from age-related macular degeneration. It is hypothesized that the
implant may promote the release of neuroprotective
factors that may slow the progression of retinal degenerative disease.
Experiencing symptoms like these? Learn about our Eye Department or book a consultation with Dr. Dhaval Patel.
Among Top 30 Ophthalmology Blog
